In adults, insulin glargine (a long-acting insulin analog) reduces the risk of nocturnal hypoglycemia and improves control of morning blood glucose levels; however, most published studies included ...

Objective—Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. The long duration of action and decreased ...

Lilly and Boehringer Ingelheim have gained EU approval for their biosimilar version of Sanofi's blockbuster insulin product Lantus (insulin glargine). The Europe-wide approval is the first ever ...

There is good news for Mainers who rely on insulin according to our media partners WMTW. Maine Attorney General Aaron Frey announced a settlement agreement Tuesday with Sanofi-Aventis U.S. following ...